Thanks cityslickers ...... okay so let's say 40,000,000 diabetics (out of 400,000,000 worldwide) with eGFR<60 times $1500 per year for apabetalone ...... that is $60,000,000,000 in annual sales for that segment alone

Okay ..... feeling a little better about today's data data data

For your China example, should the China DA accept P=0.06 ..... 115,000,000 Chinese diabetics prophylactically taking apabetalone no matter the eGFR (as a "scenario") times $1500 per year for apabetalone ...... that is $172,500,000,000 in annual sales in that scenario

.... um, appears there is room for price adjusting for apabetalone, and/or selectively minimizing the utilization criteria/segments ...... and still doing quite well.

Okay, I can visualize a little better now why we should be excited about today's revelations, and why we should have the attention of some BP's. Even with some more studies needed, it does look like there is a generous market opportunity potentially available soon maybe, or at least worthy of a significant investmentt for a qualified and interested BP ... feeling better, thank you.